This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.
| Registry number | NCT06445075 |
|---|---|
| Status | Completed |
| Phase | Phase 2 |
| Sponsor | Scholar Rock, Inc. |
| Enrollment | 102 participants |
| Design | Interventional, Randomized, Parallel, Masking: Quadruple |
| Conditions | Overweight and Obesity |
| Interventions | Apitegromab; Placebo; Tirzepatide |
| Start | May 21, 2024 |
| Primary completion | Mar 4, 2025 |
| Study completion | Jun 17, 2025 |
| Results posted | Not yet |
| Registry last updated | Jan 23, 2026 |
Compounds on this site that cite this trial
What the registry says the trial is about
A phase 2 study to evaluate the effects of apitegromab as an adjunctive therapy to GLP-1 receptor agonist therapy in subjects with overweight or obesity
Primary outcomes
These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.
| Outcome measure | Time frame |
|---|---|
| Change from Baseline in total Lean Body Mass (kg) at 24 weeks | Baseline and 24 weeks |
10 secondary outcomes also registered. See the registry record for the full list.
Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Oct 3, 2026. See the trial changes feed for what has changed recently.
